

# BioClinical Group

Division of Advanced Magnetics Inc.  
45 SPINELLI PLACE • CAMBRIDGE, MASSACHUSETTS 02138  
TELEPHONE (617) 497-2070  
Telex: 95-1417 TX Network BSN Ref: BIOC

August 24, 1984

Thomas T. Martin, Director  
Division of Engineering & Technical Programs  
U.S. Nuclear Regulatory Commission  
631 Park Avenue  
King of Prussia, PA 19406

Re: Inspection No. 30-19371/84-01  
Docket Nos. 030-19371  
030-19621  
030-19620

Dear Mr. Martin:

BioClinical Group is committed to maintaining full compliance with U.S. NRC Regulations and to keeping radiation levels and exposures as low as is reasonably achievable. As a result of the inspection conducted on July 31, 1984, and subsequent letter and Appendix A of August 17, 1984, BioClinical Group is providing this response of actions that will be taken to assure full compliance. For legal purposes, this letter should not be construed as either an admission or denial of the observations noted during this inspection.

1. A thyroid phantom has been purchased for use in the calibration of Ludlum ratemeters used for thyroid monitoring. When received, the phantom will be used for calibration at least every six months. Full compliance will be achieved by September 30, 1984.

2. The statement in the violation that survey instruments had not been calibrated for over twelve months is incorrect. Survey instruments are calibrated in-house every six months and records of these calibrations were given to Mr. McFadden.

A discussion of having the instruments calibrated by a service company in addition to the in-house calibration was held with Mr. McFadden. We assume that this is what Item 2 refers to. A service company has been contacted and arrangements made for a yearly calibration of survey instruments in addition to our semi-annual calibration. A service contract will be maintained for yearly calibration of survey instruments and any additional instruments purchased will be added to the contract to assure continued compliance. Full compliance will be achieved by September 30, 1984.

3. Instruments for measuring hood flow rates had been placed inside hoods for continual hood flow rate measurement. Monthly hood flow rate measurements were discontinued because of the new instruments. As of August 1, 1984, monthly hood flow rate measurements have resumed and will continue in addition to the permanent hood flow rate monitors. Full compliance has been achieved as of August 1, 1984.


8409100306 840824  
NMS LIC30  
20-20526-01 PDR

1-207  
1/0

Thomas T. Martin, Director  
Division of Engineering & Technical Programs  
U.S. Nuclear Regulatory Commission

If you should have any questions concerning this response, please do not hesitate to contact me. BioClinical Group is committed to achieving and maintaining full compliance. BioClinical Group is also at this time submitting license amendment application to reflect the changes in Company name and mailing address as discussed with Mr. McFadden.

Very truly yours,



Mark C. Roessel  
Director of Regulatory Affairs

MCR/amc